Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Delapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 11/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delapril SCHEMBL28170907 | 1.00 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL9725903 | 1.00 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL34120 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL20840151 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL3205477 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL6511960 | 0.99 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL9725914 | 0.98 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL9725986 | 0.98 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL10533633 | 0.98 | ACE (0.58) | ACEABCB11LMNAPDE3AMEN1 | |
| Delapril SCHEMBL1133648 | 0.97 | ACE (0.57) | ACEABCB11LMNAPDE3AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2255 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109072168-B | Agriculturally advantageous microorganisms, microbial compositions and consortia | 生物联盟有限公司 | 2023-07-07 | — | — | CN | claimed |
| EP-3529611-B1 | METHODS FOR SCREENING B CELL LYMPHOCYTES | BERKELEY LIGHTS INC (US) | 2022-11-23 | — | — | EP | claimed |
| EP-2061803-B2 | PROCESS FOR THE PURIFICATION OF FC-CONTAINING PROTEINS | ARES TRADING SA (CH) | 2022-11-16 | — | — | EP | claimed |
| CN-115252814-A | Cyclodextrin-metal organic framework composition and preparation method thereof | 中国科学院上海药物研究所 | 2022-11-01 | — | — | CN | claimed |
| CN-111405895-A | Controlled release pharmaceutical composition and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2020-07-10 | — | — | CN | claimed |
| EP-2205639-B1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME (US) | 2015-12-23 | — | — | EP | claimed |
| US-20140161798-A1 | ANTI-PCSK9 AND METHODS FOR TREATING LIPID AND CHOLESTEROL DISORDERS | MERCK SHARP & DOHME CORP. (US) | 2014-06-12 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| WO-2012054438-A1 | ANTI-PCSK9 | SCHERING CORPORATION (US) | 2012-04-26 | — | — | WO | claimed |
| EP-0412594-A2 | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-02-13 | — | — | EP | claimed |
| EP-0411766-A1 | Substituted quinazolinones as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-02-06 | — | — | EP | claimed |
| EP-0409332-A2 | Substituted triazoles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-01-23 | — | — | EP | claimed |
| EP-0407102-A1 | Substituted imidazo-fused 5-membered ring heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1991-01-09 | — | — | EP | claimed |
| EP-0400974-A2 | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | claimed |
| EP-0401030-A2 | Angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | claimed |
| EP-0400835-A1 | Substituted benzimidazoles as angiotensin II antagonists | MERCK & CO. INC. (US) | 1990-12-05 | — | — | EP | claimed |
| US-4822818-A | ANTIHYPERTENSIVE AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-04-18 | — | — | US | claimed |
| EP-0051391-B1 | BICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1984-09-05 | — | — | EP | claimed |
| EP-0051391-A1 | Bicyclic compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-05-12 | — | — | EP | claimed |